⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8229214 | 1.00 | — | — | |
| SCHEMBL13717518 | 1.00 | — | — | |
| SCHEMBL13018009 | 1.00 | — | — | |
| SCHEMBL13718133 | 1.00 | — | — | |
| SCHEMBL8010419 | 1.00 | — | — | |
| SCHEMBL8226973 | 1.00 | — | — | |
| Hydrochloric Acid SCHEMBL7872754 | 0.98 | — | — | |
| SCHEMBL19113945 | 0.84 | — | — | |
| SCHEMBL2743263 | 0.83 | TDP1 (0.32) | — | |
| SCHEMBL19574273 | 0.83 | TDP1 (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230348517-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF OCULAR DISORDERS | Azura Ophthalmics Ltd. (IL) | 2023-11-02 | — | — | US | disclosed |
| US-11643429-B2 | Compounds and methods for the treatment of ocular disorders | Azura Ophthalmics Ltd. (IL) | 2023-05-09 | — | — | US | disclosed |
| EP-2681222-B1 | PROCESS FOR PREPARATION OF KETOLIDE INTERMEDIATES | WOCKHARDT LTD (IN) | 2018-02-28 | — | — | EP | disclosed |
| WO-2017194452-A1 | SECO MACROLIDE COMPOUNDS | FIDELTA D.O.O. (HR) | 2017-11-16 | — | — | WO | disclosed |
| US-20170313661-A1 | KINASE MODULATORS FOR THE TREATMENT OF CANCER | SYNOVO GMBH (DE) | 2017-11-02 | — | — | US | disclosed |
| WO-2017118690-A1 | A NOVEL SYNTHETIC PATHWAY TOWARDS SOLITHROMYCIN AND PURIFICATION THEREOF | LEK PHARMACEUTICALS D.D. (SI) | 2017-07-13 | — | — | WO | disclosed |
| EP-3190122-A1 | A NOVEL SYNTHETIC PATHWAY TOWARDS SOLITHROMYCIN AND PURIFICATION THEREOF | LEK Pharmaceuticals d.d. (SI) | 2017-07-12 | — | — | EP | disclosed |
| EP-1253153-B1 | Process for preparing 4\"-substituted-9-deoxo-9a-aza-9a-homoerythromycin A derivatives | ZOETIS SERVICES LLC (US) | 2016-11-02 | — | — | EP | disclosed |
| EP-2938623-B1 | SELECTED MACROLIDES WITH PDE4-INHIBITING ACTIVITY | BASILEA PHARMACEUTICA AG (CH) | 2016-10-05 | — | — | EP | disclosed |
| WO-2014102315-A1 | SELECTED MACROLIDES WITH PDE4-INHIBITING ACTIVITY | BASILEA PHARMACEUTICA AG (CH) | 2014-07-03 | — | — | WO | disclosed |
| US-20080146654-A1 | Motilide polymorphs | KOSAN BIOSCIENCES INCORPORATED | 2008-06-19 | — | — | US | disclosed |
| EP-1345954-B1 | METHODS UTILIZING ARYL THIOIMINES IN SYNTHESIS OF ERYTHROMYCIN DERIVATIVES | ABBOTT LAB (US) | 2008-06-04 | — | — | EP | disclosed |
| US-7348309-B2 | Glycorandomization and production of novel vancomycin analogs | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2008-03-25 | — | — | US | disclosed |
| WO-2008017696-A1 | NEW MACROLIDES USEFUL AGAINST INFLAMMATORY AND ALLERGIC DISSEASES | BASILEA PHARMACEUTICA AG (CH) | 2008-02-14 | — | — | WO | disclosed |
| WO-2007125414-A2 | 9A-SUBSTITUTED AZALIDES FOR THE TRATMENT OF MALARIA | GLAXOSMITHKLINE ISTRAZIVACKI CENTAR ZAGREB D.O.O. (GB) | 2007-11-08 | — | — | WO | disclosed |
| WO-2007115278-A2 | 3,6,11-TRICYCLOLIDE | ENANTA PHARMACEUTICALS, INC. (US) | 2007-10-11 | — | — | WO | disclosed |
| WO-2007054296-A1 | MACROLONES | GLAXO GROUP LIMITED (GB) | 2007-05-18 | — | — | WO | disclosed |
| US-6884604-B2 | Glycorandomization and the production of novel erythronolide and coumarin analogs | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2005-04-26 | — | — | US | disclosed |
| US-20040259228-A1 | Glycorandomization and production of novel vancomycin analogs | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2004-12-23 | — | — | US | disclosed |
| US-20030068669-A1 | Glycorandomization and the production of novel erythronolide and coumarin analogs | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 2003-04-10 | — | — | US | disclosed |